drugset / Trial / NCT00381680

Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

NCT00381680

RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized phase III trial is studying low-dose vincristine to see how well it works compared with high-dose vincristine when given together with different combination chemotherapy regimens in treating young patients with intermediate-risk relapsed B-cell acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving the drugs in different ways and different doses may kill more cancer cells..

Timeline

Start
2007-03
Primary completion
2016-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Vincristine Small molecule Intravenous
Background Cyclophosphamide Other / unclassified Intravenous
Background Cytarabine Small molecule Intrathecal
Background Dexamethasone Small molecule Oral
Background Doxorubicin Other / unclassified Intravenous
Background Etoposide Small molecule Intravenous
Background Leucovorin Small molecule Intravenous
Background MERCAPTOPURINE ANHYDROUS Small molecule Oral
Background Methotrexate Small molecule Intrathecal
Background Pegaspargase Protein / enzyme biologic Intramuscular
Background Prednisone Other / unclassified Oral
Background asparaginase Protein / enzyme biologic Intramuscular
Background filgrastim Protein / enzyme biologic Intravenous